세계의 급성 관상동맥 증후군 시장 : 유형별, 제품별, 최종 사용자별 - 예측(2025-2030년)

The Acute Coronary Syndrome Market was valued at USD 1.82 billion in 2023, expected to reach USD 1.94 billion in 2024, and is projected to grow at a CAGR of 6.76%, to USD 2.89 billion by 2030.

Acute Coronary Syndrome (ACS) encompasses a spectrum of conditions associated with sudden, reduced blood flow to the heart, typically characterized by chest pain or discomfort. It includes conditions such as myocardial infarction and unstable angina, demanding precise market analysis due to its critical nature and increasing prevalence. The necessity of early diagnosis and treatment of ACS is vital to reduce morbidity and mortality rates, highlighting the application of advanced diagnostic tools and therapeutic interventions. The end-use scope primarily involves hospitals, ambulatory care centers, and diagnostic laboratories armed with emerging technologies to combat ACS effectively. The market is strongly influenced by the growing geriatric population, increasing incidence of lifestyle-related risk factors, and advancements in medical technology such as biomarker-based tests and point-of-care testing. Opportunities lie in the development of personalized medicine, integration of artificial intelligence for predictive analytics, and innovations in stent technology and pharmacotherapy. Barriers to growth include high costs of treatment, stringent regulatory frameworks, and limited accessibility in developing regions. To capitalize on these opportunities, companies can focus on strategic partnerships, research in genetic profiling for risk assessment, and the development of cost-effective solutions tailored to emerging markets. Innovation can flourish in areas like non-invasive diagnostic methods, wearable monitoring devices, and improved drug delivery systems. The market nature is highly competitive yet ripe for disruption with a constant push towards superior patient outcomes and efficiency in healthcare delivery. Companies must also adapt to the shift towards value-based care models, emphasizing overall patient experiences and long-term health benefits. By leveraging technology and focusing on patient-centric innovation, stakeholders can navigate the challenges and propel market growth in the ACS sector effectively.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Acute Coronary Syndrome Market

The Acute Coronary Syndrome Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of cardiovascular diseases worldwide
  • Inclination toward early diagnosis and treatment of diseases
  • Rise in drug discovery and drug development process
• Market Restraints
  • High cost of treatment of acute-coronary-syndrome
• Market Opportunities
  • Advancements in the treatment of acute-coronary-syndrome
  • Ongoing R&D for development of enhanced diagnostic devices and treatment for acute-coronary-syndrome
• Market Challenges
  • Stringent regulatory requirement for approval of drugs and devices for acute-coronary-syndrome treatment

Porter's Five Forces: A Strategic Tool for Navigating the Acute Coronary Syndrome Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Acute Coronary Syndrome Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Acute Coronary Syndrome Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Acute Coronary Syndrome Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Acute Coronary Syndrome Market

A detailed market share analysis in the Acute Coronary Syndrome Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Acute Coronary Syndrome Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Acute Coronary Syndrome Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Acute Coronary Syndrome Market

A strategic analysis of the Acute Coronary Syndrome Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Acute Coronary Syndrome Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Amgen Inc., AstraZeneca PLC, Baxter International, Inc., Bayer AG, bioMerieux SA, Boehringer Ingelheim International GmbH, Boston Scientific Corporation, DAIICHI SANKYO COMPANY, LIMITED, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., Johnson & Johnson Service, Inc., Koninklijke Philips N.V., Medtronic PLC, Merck & Co, Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., Siemens AG, Terumo Corporation, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Acute Coronary Syndrome Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Non-St-Elevation Myocardial Infarction (NSTEMI), St-Elevation Myocardial Infarction (STEMI), and Unstable Angina.
• Based on Offering, market is studied across Blood Tests, Imaging, and Stress Test.
• Based on End User, market is studied across Academic Institutes, Diagnostic Centers, and Hospitals & Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of cardiovascular diseases worldwide
    • 5.1.1.2. Inclination toward early diagnosis and treatment of diseases
    • 5.1.1.3. Rise in drug discovery and drug development process
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of treatment of acute-coronary-syndrome
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in the treatment of acute-coronary-syndrome
    • 5.1.3.2. Ongoing R&D for development of enhanced diagnostic devices and treatment for acute-coronary-syndrome
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulatory requirement for approval of drugs and devices for acute-coronary-syndrome treatment
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Acute Coronary Syndrome Market, by Type

• 6.1. Introduction
• 6.2. Non-St-Elevation Myocardial Infarction (NSTEMI)
• 6.3. St-Elevation Myocardial Infarction (STEMI)
• 6.4. Unstable Angina

7. Acute Coronary Syndrome Market, by Offering

• 7.1. Introduction
• 7.2. Blood Tests
• 7.3. Imaging
• 7.4. Stress Test

8. Acute Coronary Syndrome Market, by End User

• 8.1. Introduction
• 8.2. Academic Institutes
• 8.3. Diagnostic Centers
• 8.4. Hospitals & Clinics

9. Americas Acute Coronary Syndrome Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Acute Coronary Syndrome Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Acute Coronary Syndrome Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Amgen Inc.
• 3. AstraZeneca PLC
• 4. Baxter International, Inc.
• 5. Bayer AG
• 6. bioMerieux SA
• 7. Boehringer Ingelheim International GmbH
• 8. Boston Scientific Corporation
• 9. DAIICHI SANKYO COMPANY, LIMITED
• 10. Dr. Reddy's Laboratories Ltd.
• 11. Eli Lilly and Company
• 12. F. Hoffmann-La Roche Ltd.
• 13. Gilead Sciences, Inc.
• 14. Johnson & Johnson Service, Inc.
• 15. Koninklijke Philips N.V.
• 16. Medtronic PLC
• 17. Merck & Co, Inc.
• 18. Novartis AG
• 19. Pfizer Inc.
• 20. Regeneron Pharmaceuticals Inc.
• 21. Sanofi S.A.
• 22. Siemens AG
• 23. Terumo Corporation
• 24. Teva Pharmaceutical Industries Ltd.